6505--2026-2027 Influenza Virus Vaccine

The Department of Veterans Affairs National Acquisition Center is seeking to procure 2026-2027 Influenza Virus Vaccines through solicitation 36E79725R0064, specifically requesting pre-filled single dose syringes for multiple federal agencies including VA facilities, Bureau of Prisons, Indian Health Services, and Captain James A. Lovell Federal Health Care Center. The vaccines must be FDA-approved, latex and preservative-free quadrivalent or trivalent formulations with expiration dates no earlier than May 31, 2027, targeting different age groups including general population (36+ months), seniors 65 and older, and pediatric vaccines for children 6-35 months. The solicitation covers nine line items with delivery scheduled in two shipments between August 15 and October 15, 2026. While the evaluation criteria are not specified in the available documentation, the procurement includes a 0.5% cost recovery fee. The proposal submission deadline is October 23, 2025, giving potential contractors two weeks to respond from the October 9, 2025 posting date.

This opportunity is set aside for small businesses operating under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) with a size standard of 1,300 employees, and no current incumbent contractors are identified. The total estimated annual usage includes significant quantities: 153,679 doses for the general population line item, 132,545 doses for senior-specific vaccines, and 1,000 doses for pediatric vaccines, though specific award values or budget ranges are not disclosed in the available documentation. The vaccines will serve multiple federal healthcare systems across various locations where VA facilities, federal prisons, Indian Health Services locations, and the Captain James A. Lovell Federal Health Care Center operate. Performance will require coordination across these diverse federal healthcare delivery points to ensure timely distribution of influenza vaccines for the 2026-2027 flu season. The procurement timeline spans from the current solicitation phase through vaccine delivery completion by October 15, 2026.